Researchers have identified various factors associated with mortality following a diagnosis with the COVID-19 virus among recipients of allogeneic and autologous HCT.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
A multicenter team reported on the administration of COVID-19 convalescent plasma to patients with severe COVID-19 in the Yale-New Haven Health System.
Elective cancer surgery within COVID-19–free surgical pathways results in lower pulmonary complication, SARS-CoV-2 infection, and mortality rates.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
The prevalence of H pylori infection continues to fall in the general population with only 16% of all gastric and 25% of all duodenal patients with ulcer harboring H pylori.
Prospective studies are needed to determine what changes are significantly associated with treatment, whether these changes are causes or effects of response, and whether the composition of the intestinal microbiome can be used to select treatments for patients with IBD.
Patients with viral respiratory infections exhibited poorer outcomes following transplantation compared with patients without infection.
